November 6, 2007 - Acusphere Inc. announced that Imagify Perfusion Stress Echo, an investigational new drug developed to assess perfusion using ultrasound (or echocardiography) for the detection of coronary heart disease, was shown to be just as good at determining whether or not a patient has disease (accuracy), according to data from two studies released today at the AHA meeting.

November 2007 - Boston Scientific, a manufacturer of intravascular ultrasound (IVUS) imaging technology, unveiled new software enhancements to the iLab Ultrasound Imaging System at AHA 2007.
The release of the new iLab System Software enhancements brings iSize, iColor and iTint features directly to the cath lab reportedly giving physicians the ability to preview device sizing decisions, colorize plaque and blood flow and overlay color to enrich viewing the IVUS image. Since launching the iLab System in May of 2006, Boston Scientific has placed more than 500 systems worldwide.

November, 2007 - Biosound Esaote introduced the XVision upgrade module for the MyLab 25, MyLab 30CV and MyLab 50 platforms at AHA 2007.
The XVision upgrade incorporates the new XView algorithms, which reportedly deliver a stronger and more enhanced image quality through Biosound’s MyLab ultrasound systems. XView is an algorithm that reportedly provides a significant reduction in speckle (noise) without the disadvantages found in other techniques.

For more information: www.biosound.com

November 5, 2007 - New data released today at the American Heart Association's Scientific Sessions showed that Abbott's SIMCOR, an investigational, fixed-dose combination of Abbott's proprietary extended-release niacin, Niaspan, and simvastatin, met its primary endpoint of lowering plaque-promoting non-HDL cholesterol (total cholesterol minus HDL), while demonstrating improvements on other key lip

November 4, 2007 - Itamar Medical announced that four presentations at AHA, including one from the Framingham Heart Study, link PAT signal with several cardiovascular conditions and risk factors as the technology gains broader acceptance.

The Endo-PAT, developed by Itamar Medical, is a FDA approved noninvasive device that detects a pathology called endothelial dysfunction. The condition refers to an impairment of the endothelial layer and is emerging as a key precursor for the development of atherosclerosis.